PANVAC

AXP000179.1 · Cancer vaccine

Platform
poxvirus prime-boost (vaccinia prime, fowlpox boost)
Targets
CEACAM5; MUC1
Originator
Therion Biologics

Names

NameTypeSource
PANVAC ambiguouspreferred name, codecurator, curator
falimarevINNncit
inalimarevINNncit
PANVAC-Fcodencit
PANVAC-Vcodencit
PANVAC-VFcodectgov
TBC-PAN-003codectgov

Virus

Role
Vaccine vector
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Strain
PANVAC-V (vaccinia) prime; PANVAC-F (fowlpox) boost
Replication
replicating
Modifications
CEA(D609), MUC1(L93) and TRICOM cassettes; replication-competent vaccinia prime, non-replicating fowlpox boost
Transgenes
CEACAM5, MUC1, CD80, ICAM1, CD58
Route
subcutaneous
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (6)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT02015104Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCGCompletedPhase 22013-12-182018-09-1832Bladder Cancer
NCT00669734Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By SurgeryActive not recruitingPhase 12010-02-012021-09-0218Locally Advanced Pancreatic Adenocarcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IV Pancreatic Cancer AJCC v6 and v7
NCT00179309Docetaxel Alone or in Combination With Vaccine to Treat Breast CancerCompletedPhase 22005-092013-0248Breast Cancer
NCT00103142Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal CancerCompletedPhase 22005-022009-0674Colorectal Cancer; Metastatic Cancer
NCT00088413PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced CancerCompletedPhase 1/22004-07-212018-04-0151Adenocarcinoma; Breast Cancer; Colorectal Cancer; Ovarian Cancer
NCT00088660PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing RegimenUnknownPhase 32004-06250Pancreatic Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40443562Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research.The breast journal2025cited by trial NCT00088413
PMID 40781051Bacillus Calmette-Guérin (BCG) in combination with PANVAC™ vs. BCG alone in adults with high-grade BCG-refractory non-muscle-invasive bladder cancer.Urologic oncology2025name in title: PANVAC
PMID 26291768Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.JAMA oncology2015cited by trial NCT00179309
PMID 23657083A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.Annals of surgery2013cited by trial NCT00103142
PMID 22068656A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.Clinical cancer research : an official journal of the American Association for Cancer Research2011cited by trial NCT00088413
PMID 18483372Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research2008cited by trial NCT00088413
PMID 18039393Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer.Journal of translational medicine2007name in abstract: PANVAC-V

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 39453092Partial Sequence Analysis of Commercial Peste des Petits Ruminants Vaccines Produced in Africa.Veterinary sciences2024name in abstract: PANVAC
PMID 37684280The evaluation of five serological assays in determining seroconversion to peste des petits ruminants virus in typical and atypical hosts.Scientific reports2023name in abstract: PANVAC
PMID 35158964From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC).Cancers2022name in abstract: PANVAC
PMID 30626434Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.Journal for immunotherapy of cancer2019name in abstract: PANVAC
PMID 31110074A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.Clinical cancer research : an official journal of the American Association for Cancer Research2019name in abstract: PANVAC
PMID 31131993Detection and molecular characterization of Peste des Petits Ruminants virus from outbreaks in Burundi, December 2017-January 2018.Transboundary and emerging diseases2019name in abstract: PANVAC
PMID 31635322Development and Evaluation of Epitope-Blocking ELISA for Detection of Antibodies against Contagious Caprine Pleuropneumonia in Goat Sera.Veterinary sciences2019name in abstract: PANVAC
PMID 29520689Development and validation of an epitope-blocking ELISA using an anti-haemagglutinin monoclonal antibody for specific detection of antibodies in sheep and goat sera directed against peste des petits ruminants virus.Archives of virology2018name in abstract: PANVAC
PMID 27485137Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy.Cancer immunology research2016name in abstract: PANVAC
PMID 22380820Outlining novel scenarios for improved therapeutic cancer vaccines: the PANVAC paradigm.Expert review of vaccines2012name in title: PANVAC
PMID 22595052Clinical evaluation of TRICOM vector therapeutic cancer vaccines.Seminars in oncology2012name in abstract: PANVAC
PMID 22892452Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC).Journal of immunotherapy (Hagerstown, Md. : 1997)2012name in title: PANVAC
PMID 19907722Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2009name in abstract: inalimarev
PMID 19088949Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2008name in abstract: inalimarev
PMID 17373905PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma.Expert opinion on biological therapy2007name in title: PANVAC-VF
PMID 16451103Development of the PANVAC-VF vaccine for pancreatic cancer.Expert review of vaccines2006name in title: PANVAC-VF
PMID 16512998A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma.Clinical colorectal cancer2006name in title: PANVAC
PMID 16800982A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229).Clinical breast cancer2006name in title: PANVAC-V
PMID 8593393Contagious bovine pleuropneumonia vaccines: the need for improvements.Revue scientifique et technique (International Office of Epizootics)1995name in abstract: PANVAC
PMID 8639954Regulatory framework and requirements for managing risks associated with veterinary biological products in Africa: present systems and future needs.Revue scientifique et technique (International Office of Epizootics)1995name in abstract: PANVAC
PMID 8639956The role of international and regional organisations in the regulation of veterinary biologicals.Revue scientifique et technique (International Office of Epizootics)1995name in abstract: PANVAC

NIH grants

ProjectTitleOrganisationPIYearsLinked by
ZIABC010598Human Immune Responses to Tumor Antigens for Cancer ImmunotherapyDIVISION OF BASIC SCIENCES - NCISCHLOM, JEFFREY2012–2025name in abstract: PANVAC
ZIABC010666Cancer ImmunotherapyDIVISION OF BASIC SCIENCES - NCIGULLEY, JAMES L.2009–2025name in abstract: PANVAC-V
ZIABC010425Strategies for Cancer Immunotherapy Clinical TrialsDIVISION OF BASIC SCIENCES - NCISCHLOM, JEFFREY2009–2023name in abstract: PANVAC-V
ZIABC010945Clinical trials employing cancer vaccine combination therapiesDIVISION OF BASIC SCIENCES - NCIGULLEY, JAMES L.2009–2022name in abstract: PANVAC-V
ZIABC011547Cancer Immunotherapy Clinical TrialsDIVISION OF BASIC SCIENCES - NCISTRAUSS, JULIUS2014–2022name in abstract: PANVAC
ZICBC011044Tissue Processing-Sequencing FacilityDIVISION OF BASIC SCIENCES - NCIVOCKE, CATHY D2015–2022name in abstract: PANVAC
ZIABC011865Breast and Other Carcinoma Clinical Trials Using ImmunotherapiesDIVISION OF BASIC SCIENCES - NCIGATTI-MAYS, MARGARET2019–2020name in abstract: PANVAC
ZIABC011528A Randomized, Prospective, Phase II Study to Determine the Efficacy of BacillusDIVISION OF BASIC SCIENCES - NCIAGARWAL, PIYUSH2013–2019name in abstract: PANVAC
ZIABC010972Identification of human tumor-associated antigensDIVISION OF BASIC SCIENCES - NCITSANG, KWONG YOK2009–2016name in abstract: PANVAC-V
ZIABC011281Combination therapies involving novel cancer vaccinesDIVISION OF BASIC SCIENCES - NCIMADAN, RAVI2010–2013name in abstract: PANVAC-V
ZIABC011280Cancer Therapy Trials using novel vaccine platformsDIVISION OF BASIC SCIENCES - NCIMADAN, RAVI2010–2012name in abstract: PANVAC-V
M01RR001070CLINICAL TRIAL: ACTIVE IMMUNOTHERAPY AFTER RESECTION OF HEPATIC METASTASES OF COMEDICAL UNIVERSITY OF SOUTH CAROLINACOLE, DAVID J2008–2008name in abstract: PANVAC-V
Z01BC010425Analysis of Human Immune Reponses in Cancer Vaccine Clinical TrialsDIVISION OF BASIC SCIENCES - NCISCHLOM, JEFFREY2006–2008name in abstract: PANVAC-V
Z01BC010666Cancer Therapy Clinical Trials Using Novel Recombinant VaccinesDIVISION OF BASIC SCIENCES - NCIGULLEY, JAMES L.2006–2008name in abstract: PANVAC-VF
Z01BC010662Vaccine Clinical TrialsDIVISION OF BASIC SCIENCES - NCIARLEN, PHILIP M2006–2007name in abstract: PANVAC-VF
Z01SC010365Optimizing the Graft-Versus-Tumor Effect in Allogeneic HDIVISION OF CLINICAL SCIENCES - NCIBISHOP, MICHAEL R2005–2006name in abstract: PANVAC

Notes

PANVAC-V (inalimarev, NCIt C29317) vaccinia prime plus PANVAC-F (falimarev, NCIt C29316) fowlpox boosts, both encoding CEA, MUC-1 and TRICOM; one program (one prime-boost product), so ncit left empty rather than pick one component concept. Phase 3 NCT00088660 (TBC-PAN-003) in metastatic pancreatic cancer after gemcitabine, sponsored by Therion Biologics; Therion wound down in 2006. NCIt lists 'PANVAC' also as a synonym of CV301 (AXP000143), which is the later MVA-BN-based remake: that alias is marked ambiguous.

How to cite

PANVAC (AXP000179.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000179.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.